Non-Vital Tooth Clinical Trial
Official title:
Effect of Piroxicam Premedication on Postendodontic Pain in Mandibular Molars With Non-vital Pulp: A Randomized Controlled Trial
The aim of the study is to evaluate the effect of piroxicam (20mg) compared to placebo on post-endodontic pain of single-visit endodontic treatment of non-vital mandibular molars.
Status | Not yet recruiting |
Enrollment | 60 |
Est. completion date | December 1, 2020 |
Est. primary completion date | September 1, 2020 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 50 Years |
Eligibility |
Inclusion Criteria: 1. Patients aging between 18-50 years old 2. Patients with mandibular molar with non-vital pulp. 3. Systemically- healthy patients (ASA I or II). 4. Patients who agree to attend for recall appointments and provide a written consent. Exclusion Criteria: 1. Pregnant or lactating female patients. 2. Patients allergic to piroxicam. 3. History of peptic ulceration. 4. Periapical abscess, fistula. 5. Non-restorable teeth. 6. Moderate or severe marginal periodontitis i.e. pocket probe>3mm. |
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
Cairo University |
Joshi N, Mathew S, George JV, Hegde S, Bhandi S, Madhu KS. Comparative evaluation of the efficacy of two modes of delivery of Piroxicam (Dolonex(®)) for the management of postendodontic pain: A randomized control trial. J Conserv Dent. 2016 Jul-Aug;19(4):301-5. doi: 10.4103/0972-0707.186454. — View Citation
Konagala RK, Mandava J, Pabbati RK, Anupreeta A, Borugadda R, Ravi R. Effect of pretreatment medication on postendodontic pain: A double-blind, placebo-controlled study. J Conserv Dent. 2019 Jan-Feb;22(1):54-58. doi: 10.4103/JCD.JCD_135_18. — View Citation
Nekoofar MH, Sadeghipanah M, Dehpour AR. Evaluation of meloxicam (A cox-2 inhibitor) for management of postoperative endodontic pain: a double-blind placebo-controlled study. J Endod. 2003 Oct;29(10):634-7. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Postendodontic pain using a pain-measuring scale | Postoperative pain is measured using the Numerical Rating Scale (NRS) which is an 11-point scale from 0-10 where 0 represents no pain and 10 represents the worst pain measured 6 hours after the first visit | 6 hours | |
Primary | Postendodontic pain using a pain-measuring scale | Postoperative pain is measured using the Numerical Rating Scale (NRS) which is an 11-point scale from 0-10 where 0 represents no pain and 10 represents the worst pain measured 12 hours after the first visit | 12 hours | |
Primary | Postendodontic pain using a pain-measuring scale | Postoperative pain is measured using the Numerical Rating Scale (NRS) which is an 11-point scale from 0-10 where 0 represents no pain and 10 represents the worst pain measured 24 hours after the first visit | 24 hours | |
Primary | Postendodontic pain using a pain-measuring scale | Postoperative pain is measured using the Numerical Rating Scale (NRS) which is an 11-point scale from 0-10 where 0 represents no pain and 10 represents the worst pain measured 48 hours after the first visit | 48 hours | |
Primary | Postendodontic pain using a pain-measuring scale | Postoperative pain is measured using the Numerical Rating Scale (NRS) which is an 11-point scale from 0-10 where 0 represents no pain and 10 represents the worst pain measured 72 hours after the first visit | 72 hours | |
Primary | Postendodontic pain using a pain-measuring scale | Postoperative pain is measured using the Numerical Rating Scale (NRS) which is an 11-point scale from 0-10 where 0 represents no pain and 10 represents the worst pain measured 7 days after the first visit | 7 days | |
Secondary | Analgesic medication intake incidence | Analgesic medication intake incidence (Yes/No) as a rescue medication in case postoperative pain persisted after the sham medication intake. | 7 days |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05801354 -
Turmeric Gel as Alternative Non-vital Pulpotomy Medicament in Primary Teeth
|
Phase 1/Phase 2 | |
Completed |
NCT05801367 -
Allium Sativum Oil as Alternative Non-vital Pulpotomy Medicament in Primary Teeth
|
Phase 1/Phase 2 |